You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 14, 2025

CLINICAL TRIALS PROFILE FOR RIOMET


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Riomet

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00087516 ↗ Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021) Completed Merck Sharp & Dohme Corp. Phase 3 2004-06-01 The purpose of this clinical study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.
NCT00443755 ↗ Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance Completed National Center for Research Resources (NCRR) Phase 2 2005-08-01 The objective of this study is to determine whether targeted pharmacological improvement of insulin sensitivity will normalize the associated elevations of thrombotic and inflammatory cardiovascular disease (CVD) biomarkers in individuals with insulin resistance.
NCT00443755 ↗ Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Phase 2 2005-08-01 The objective of this study is to determine whether targeted pharmacological improvement of insulin sensitivity will normalize the associated elevations of thrombotic and inflammatory cardiovascular disease (CVD) biomarkers in individuals with insulin resistance.
NCT00443755 ↗ Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance Completed Takeda Pharmaceuticals North America, Inc. Phase 2 2005-08-01 The objective of this study is to determine whether targeted pharmacological improvement of insulin sensitivity will normalize the associated elevations of thrombotic and inflammatory cardiovascular disease (CVD) biomarkers in individuals with insulin resistance.
NCT00443755 ↗ Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance Completed Mayo Clinic Phase 2 2005-08-01 The objective of this study is to determine whether targeted pharmacological improvement of insulin sensitivity will normalize the associated elevations of thrombotic and inflammatory cardiovascular disease (CVD) biomarkers in individuals with insulin resistance.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Riomet

Condition Name

Condition Name for Riomet
Intervention Trials
Insulin Resistance 4
Type 2 Diabetes Mellitus 4
Type 2 Diabetes 3
Diabetes 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Riomet
Intervention Trials
Diabetes Mellitus 11
Diabetes Mellitus, Type 2 7
Insulin Resistance 5
Metabolic Syndrome X 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Riomet

Trials by Country

Trials by Country for Riomet
Location Trials
United States 146
South Africa 4
Canada 4
Mexico 4
Puerto Rico 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Riomet
Location Trials
Pennsylvania 7
Ohio 7
California 7
North Carolina 6
Utah 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Riomet

Clinical Trial Phase

Clinical Trial Phase for Riomet
Clinical Trial Phase Trials
Phase 4 9
Phase 3 7
Phase 2/Phase 3 2
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Riomet
Clinical Trial Phase Trials
Completed 18
Recruiting 7
Active, not recruiting 6
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Riomet

Sponsor Name

Sponsor Name for Riomet
Sponsor Trials
National Cancer Institute (NCI) 6
Merck Sharp & Dohme Corp. 4
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Riomet
Sponsor Trials
Other 44
NIH 19
Industry 19
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials, Market Analysis, and Projections for RIOMET ER

Introduction to RIOMET ER

RIOMET ER, developed by Sun Pharmaceutical Industries Ltd., is an extended-release oral suspension formulation of metformin, approved by the U.S. Food and Drug Administration (FDA) in August 2019. This formulation is designed to improve glycemic control in patients with type 2 diabetes mellitus, particularly those who may have difficulty swallowing tablets or require a more convenient dosing regimen[4].

Clinical Trials and Development

Approval and Launch

RIOMET ER was approved as an adjunct to diet and exercise to improve glycemic control in patients 10 years of age and older with type 2 diabetes mellitus. The approval was based on clinical trials that demonstrated its efficacy and safety in managing blood glucose levels[4].

Clinical Trial Design

While specific details on the clinical trials leading to the approval of RIOMET ER are not provided in the sources, typical clinical trials for metformin formulations involve several phases:

  • Phase I: Focuses on safety and tolerability in a small group of healthy volunteers.
  • Phase II: Evaluates efficacy and side effects in a larger group of patients with the condition.
  • Phase III: Large-scale trials comparing the new drug to existing treatments to confirm efficacy, monitor side effects, and compare it to commonly used treatments.

For RIOMET ER, these trials would have been conducted to ensure that the extended-release formulation is as effective and safe as other metformin products.

Market Analysis

Current Market Size and Growth

The global metformin hydrochloride market, which includes formulations like RIOMET ER, was valued at approximately USD 268.95 million in 2022. This market is projected to grow to around USD 386.91 million by 2030, with a compound annual growth rate (CAGR) of roughly 4.7% between 2023 and 2030[5].

Market Drivers

Several factors are driving the growth of the metformin hydrochloride market:

  • Increasing Prevalence of Type 2 Diabetes: The growing number of people living with type 2 diabetes globally is a significant driver. As the population ages and lifestyles become more sedentary, the demand for effective diabetes management medications like metformin is increasing.
  • Convenience and Efficacy: The extended-release formulation of RIOMET ER offers a convenient once-daily dosing option, which can improve patient compliance and outcomes.
  • Regulatory Approvals: The FDA approval of RIOMET ER in the U.S. market has expanded the availability of metformin formulations, contributing to market growth.

Market Segments

The metformin hydrochloride market is segmented by application, distribution channel, and region. The Asia-Pacific region is expected to lead the market during the forecast period due to the large population and increasing prevalence of diabetes in this region[5].

Projections and Future Outlook

Market Growth Projections

The metformin hydrochloride market, including RIOMET ER, is expected to continue growing due to the increasing demand for diabetes management treatments. Here are some key projections:

  • Market Size: Expected to reach USD 386.91 million by 2030.
  • Growth Rate: A CAGR of approximately 4.7% between 2023 and 2030.
  • Regional Leadership: The Asia-Pacific region is anticipated to lead the market during the forecast period[5].

Competitive Landscape

The market for metformin hydrochloride is competitive, with several key players including Shouguang Fukang Pharmaceutical, CR Double-Crane, Wanbury, Keyuan Pharmaceutical, and others. Sun Pharmaceutical Industries Ltd., the developer of RIOMET ER, is a significant player in this market[5].

Regulatory Environment

FDA Approval and Compliance

RIOMET ER has received FDA approval, which is a critical factor in its market success. The FDA's regulatory framework ensures that drugs meet stringent safety and efficacy standards before they are approved for use. This approval enhances the credibility and marketability of RIOMET ER[4].

Key Takeaways

  • Clinical Trials: While specific details on the clinical trials for RIOMET ER are not provided, such trials are crucial for ensuring the safety and efficacy of any new drug formulation.
  • Market Size and Growth: The global metformin hydrochloride market is projected to grow from USD 268.95 million in 2022 to USD 386.91 million by 2030.
  • Market Drivers: Increasing prevalence of type 2 diabetes, convenience of the extended-release formulation, and regulatory approvals are key drivers.
  • Regional Leadership: The Asia-Pacific region is expected to lead the market during the forecast period.
  • Competitive Landscape: The market is competitive with several key players, including Sun Pharmaceutical Industries Ltd.

FAQs

What is RIOMET ER?

RIOMET ER is an extended-release oral suspension formulation of metformin, approved by the FDA for improving glycemic control in patients with type 2 diabetes mellitus.

What is the current market size of the metformin hydrochloride market?

The global metformin hydrochloride market was valued at approximately USD 268.95 million in 2022.

What is the projected growth rate of the metformin hydrochloride market?

The market is expected to grow at a CAGR of roughly 4.7% between 2023 and 2030.

Which region is expected to lead the metformin hydrochloride market during the forecast period?

The Asia-Pacific region is anticipated to lead the market during the forecast period.

What are the key drivers of the metformin hydrochloride market growth?

Key drivers include the increasing prevalence of type 2 diabetes, the convenience of the extended-release formulation, and regulatory approvals.

Sources

  1. Sun Pharma Launches RIOMET ER Oral Suspension in the U.S. - Biospace, 2020.
  2. Market Intelligence Report: Antidiabetic Drugs, 2012-2021 - Canada.ca.
  3. Clinical Trials Market Size, Trends Analysis - Mordor Intelligence.
  4. Metformin Hydrochloride Market Size, Share and Forecast 2030 - Zion Market Research.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.